It is estimated that EGPA affects between 5,600 and 14,500 people in the United States.* Most people with EGPA are not diagnosed until their late 40s or early 50s.
Depending on the organ(s) affected, other symptoms of EGPA can include shortness of breath, coughing, chest pain, skin rashes, muscle pain, joint pain, nasal discharge, facial pain, abdominal pain or bloody stools, numbness or loss of strength, tingling in hands and feet, and kidney disease.
Non-severe EGPA can be treated with steroids and drugs that suppress the immune system’s response. More severe cases are treated with steroids in combination with cyclophosphamide – a cytotoxic agent – or rituximab – a biologic agent, depending on the level of severity.
NS Pharma is currently investigating a treatment for EGPA we are developing via JAK1 protein inhibition. Our NS-229 has potent JAK1 inhibitory activity and suppresses activation of eosinophils, T cells, and B cells by inhibiting various cytokine signaling through JAK1 inhibition.
*https://acrabstracts.org/abstract/clinical-and-economic-characteristics-of-patients-diagnosed-with-eosinophilic-granulomatosis-with-polyangiitis-egpa-formerly-churg-strauss-syndrome-in-the-united-states/